{"nct_id":"NCT02186821","title":"Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)","status":"TERMINATED","status_verified_date":"2021-03","start_date":"2014-09-17","start_date_type":"ACTUAL","primary_completion_date":"2017-12-13","primary_completion_date_type":"ACTUAL","completion_date":"2017-12-13","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["NVS"]}